(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Pick Your Favored kind of soup - 2How to watch the ‘Wicked: One Wonderful Night’ special — now streaming
- 3Best Food Truck Cooking: Decision in favor of Your Number one!
- 4This ‘CSI: Miami’ star spent years solving crimes on TV. Then she became the target of one herself.
- 5Ocean side Locations for a Family Excursion
- Journey Lines for Each Explorer: Track down Your Ideal Journey
- The Response to Self-improvement: Embracing a Development Outlook
- Manual for Instructive Application for Youngsters
- The Manual for Electric Vehicles that will be hot merchants in 2023
- A mom's viral post is raising the question: Do kids need snacks? Dietitians have answers.
- Russian drone slams into block of flats in deadly wave of strikes across Kyiv
- Reconnecting with an old friend is a story of distance, loss and rediscovery
- Relentless rise in carbon pollution from fossil fuels slightly dampens climate-fighting hopes
- Coalition led by Iraqi PM al-Sudani wins parliamentary elections
